Vaishali Pharma Quarterly Results
Vaishali Pharma quarterly results. In Sept 2026, Vaishali Pharma (VAISHALI) reported revenue ₹31 Cr and net profit ₹2 Cr — revenue -8.8% YoY. View VAISHALI price range for the annual high/low range and current price position.
VAISHALI Quarterly Results — Revenue, Profit & EPS Highlights
Vaishali Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore VAISHALI price trends to track price trends across different timeframes.
- Revenue of ₹31 Cr in Sept 2026 (+10.7% vs Mar 2026, -8.8% vs Sept 2025)
- Net Profit of ₹2 Cr in Sept 2026 (+100.0% vs Sept 2025)
- EBITDA of ₹3 Cr in Sept 2026 (+200.0% vs Mar 2026)
- Operating Margin of 7.0% in Sept 2026 (+8.0pp vs Mar 2026)
- Earnings Per Share of ₹0.16 in Sept 2026 (+433.3% vs Mar 2026)
Vaishali Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VAISHALI quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 31 | 28 | 24 | 34 | 25 | 10.7% | -8.8% |
| Net Profit (₹ Cr) | 2 | 0 | 2 | 1 | 1 | - | - |
| EBITDA (₹ Cr) | 3 | 1 | 2 | 2 | 2 | - | - |
| EPS (₹) | 0.16 | 0.03 | 0.12 | 0.09 | 0.10 | - | - |
| Operating Margin (%) | 7.0% | -1.0% | 6.0% | 4.0% | 6.0% | - | - |
VAISHALI Share Price Trend — 1-Year Movement Across Quarterly Results
Vaishali Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Vaishali Pharma share price today.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VAISHALI vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vaishali Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1884.9 | 16,617 | 1,995 | +10.6% | - | 12.0% | 227.1 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11180.5 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4689.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 407.4 |
|
Apollo Hospitals
Sept 2026 |
₹132,281.88 Cr | 9200.0 | 7,673 | 660 | +15.2% | - | 8.6% | 209.9 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2294.6 | 2,219 | 436 | +21.7% | - | 19.6% | 280.9 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores